Australia's most trusted
source of pharma news
Posted 20 October 2025 AM
The PBAC ticked everything it saw at its September Intracycle meeting, including a huge drug which has been pushed strongly by patient groups but which does not yet have TGA approval.
Vertex's "Vanza triple" once-daily cystic fibrosis treatment, Alyftrek, was recommended for the treatment of cystic fibrosis in patients aged six years and older who have at least one mutation in the CFTR gene that is responsive to Alyftrek potentiation based on clinical or in vitro assay data. It's set at the same price as Trikafta and included in the risk sharing arrangement.
Please click the button to indicate that the printout of this article is for your personal use only and not for any type of redistribution.
Redistribution of the whole or part of Pharma in Focus by any means is a breach of copyright law.